阿瑞匹坦对黑色素瘤患者顺铂治疗引起恶心呕吐的止吐作用

Antiemetic Effect of Aprepitant for Cisplatin-induced Nausea and Vomiting in Melanoma Patients

目的旨在探讨阿瑞匹坦对黑色素瘤患者顺铂治疗引起的恶心呕吐的作用。方法 170例接受含顺铂方案治疗的黑色素瘤患者,随机分入阿瑞匹坦组和对照组进行预防性止吐治疗。记录患者顺铂治疗后的恶心、呕吐反应,解救治疗,功能性生活指数(呕吐)及其他不良反应。结果两组中各84例患者可评价疗效。阿瑞匹坦组患者的完全缓解率(无呕吐,无解救治疗)为69%,显著高于对照组的44%(χ2=10.683,P=0.001)。阿瑞匹坦组和对照组的呕吐发生率分别为27%和51%,阿瑞匹坦组显著优于对照组(χ2=9.982,P=0.002)。阿瑞匹坦组未观察到相关的不良反应。结论阿瑞匹坦可显著降低黑色素瘤患者中顺铂引起的呕吐反应。尽管阿瑞匹坦的安全性良好,在给药前仍需注意药物间的相互作用。

Objective To determine the efficacy of aprepitant on cisplatin-induced nausea and vomiting in melanoma patients. Methods A total of 170 patients who received cisplatin treatment, were assigned randomly into aprepitant group and control group for the prevention of nausea and vomiting. The severity of nausea and vomiting were observed during the 120 h post-cisplatin, as well as salvage treatment, functional living index-emesis, and other adverse effect. Results Eighty-four patients were evaluable in each group. Aprepitant group and control group showed an overall complete response rates of 69% and 44%(χ2=10.683, P=0.001). While the incidence of vomiting was much lower in aprepitant group than that in control goup(27% vs. 51%, χ2=9.982, P=0.002). Aprepitant-related adverse effect was not detected in the aprepitant group. Conclusion Antiemetic therapy with aprepitant improves the control of vomiting prevention in melanoma patients receiving cisplatin-based chemotherapy. Although aprepitant is safe, potential drug-drug interactions need to be considered before prescription.